We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Axxam SpA Receives Funding for the Development of Compounds for Prevention Treatment of Disability in MS
News

Axxam SpA Receives Funding for the Development of Compounds for Prevention Treatment of Disability in MS

Axxam SpA Receives Funding for the Development of Compounds for Prevention Treatment of Disability in MS
News

Axxam SpA Receives Funding for the Development of Compounds for Prevention Treatment of Disability in MS

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Axxam SpA Receives Funding for the Development of Compounds for Prevention Treatment of Disability in MS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Axxam SpA, Fast Forward LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, entered a collaboration to develop compounds for prevention treatment of disability in Multiple Sclerosis (MS).

Under the terms of this agreement, Axxam will screen its extensive chemical library to develop small molecules that target the sodium-calcium exchanger NCX1 on axons.

Molecules preventing the sodium-calcium exchanger NCX1 activation in the reverse mode, have the potential to preclude axonal injury and ultimately clinical disability in MS.

The award from Fast Forward and Merck Serono provides Axxam SpA with funding over a period of 18 months, and is distributed from the Accelerating Commercial Development Fund, which is allocated to for-profit entities and is designed to accelerate the development of research discoveries into new or improved therapies for people with multiple sclerosis.

Advertisement